Revenue will come from selling the tests to companies involved in trials. The CLIA partner will pay AMBS upfront to share in that potential revenue. At the same time, the partner will help develop the test so AMBS can eventually proceed toward FDA approval. After CLIA, another partner (or perhaps the same partner) will join AMBS to fully commercialize the test by obtaining FDA approval so it can be used in doctor's offices and other places besides clinical trials.

Please correct me if I'm wrong because that's been my understanding all along.